10-Q · May 20, 2026
DNA X, Inc. reported a substantial net income from discontinued operations driven by a completion of an asset sale, while continuing operations reflect a loss as the company transitions to a new business model focusing…
Earnings analysis · 10-Q
SONM earnings analysis
Filed August 19, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q extract does not include current-period revenue, margins, EPS, balance-sheet data, cash flow, segment results, or quantitative guidance, so operating performance versus prior periods cannot be…
Read full summary
The supplied 10-Q extract does not include current-period revenue, margins, EPS, balance-sheet data, cash flow, segment results, or quantitative guidance, so operating performance versus prior periods cannot be assessed. The principal disclosure is a material weakness in internal control over financial reporting that remained unresolved as of June 30, 2026. Management also concluded that disclosure controls were ineffective for complex investment and acquisition accounting, while stating that no material control changes occurred during the quarter.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls deemed ineffective
Management concluded that disclosure controls were not effective as of the end of the period covered by the report, specifically for accounting for complicated investment and acquisition transactions.
-
Material accounting weakness identified
The company identified a material weakness caused by insufficient personnel with technical U.S. GAAP expertise to account for complex, non-routine transactions, including business acquisitions.
-
Weakness remains unresolved
Management stated that the material weakness had not been resolved as of June 30, 2026.
-
No control remediation reported
The company reported no change in internal control over financial reporting during the three months ended June 30, 2026, that materially affected or was reasonably likely to materially affect those controls.
What to watch
-
Unresolved material weakness
A material weakness remained unresolved as of June 30, 2026, creating a reasonable possibility that a material misstatement in interim or annual financial statements would not be prevented or detected on a timely basis.
-
Complex transaction accounting risk
The company stated that it lacked sufficient technical accounting expertise to properly evaluate complex transactions, and that errors in the initial recording of certain transactions required adjustments during the financial statement close process.
-
No new risk-factor disclosure
The filing states that there were no material changes to the risk factors in the December 31, 2025 Form 10-K; therefore, no new or revised risk-factor disclosures were identified in this 10-Q.
Management's outlook
The supplied 10-Q extract contains no quantitative revenue or EPS outlook. No change to prior guidance can be assessed.
Earlier filings 4
10-K · April 30, 2026
SONM's 10-K report highlights ongoing challenges within the company, with continued losses evident in its financial results from 2025. The company aims to expand its position in the cryptocurrency sector, although no…
10-K · April 15, 2026
The company completed a strategic pivot into crypto trading by acquiring a trading platform in December 2025 and operating the platform on a limited basis as of year-end; it had four full-time employees and four…
10-Q · October 31, 2025
Sonim reported Q3 2025 net revenue of $16,214,000 and a reduced net loss of $4,753,000 (diluted EPS $(4.83)), improving vs Q3 2024 EPS of $(9.32). Gross profit compressed to $1,816,000 (11.2% margin) while operating…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.